EUVIMEDEUVIMED entdecken
Crossref

Ondansetron-loaded magnetically targeted nanocarriers for anxiety: optimization, in vitro characterization, and in vivo evaluation in rats

Norhan Tantawy, Soha Elsalhy, Jihad Mahmoud Alsofany, Abdulrahman M Saleh, Samiyah M Alshehri, Sana Saeed Alqarni, Elsayed K El-Sayed, Asmaa A Ahmed, Eman E El Naggar

European Journal of Pharmaceutics and Biopharmaceutics · 2026-06 · 223 · 115071

DOI: 10.1016/j.ejpb.2026.115071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026-06. Verfasst von Norhan Tantawy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Capital University Previously Known as Helwan University, Cairo 11790, Egyp…. Hauptthemen laut MEDLINE: Ondansetron, Drug Carriers, Anxiety, Anti-Anxiety Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 143 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigated an intranasal nose-to-brain delivery strategy to repurpose ondansetron (OND) for anxiety management using PLGA nanoparticles co-loaded with superparamagnetic iron oxide nanoparticles (SPIONs) and incorporated into a Carbopol 940 mucoadhesive gel. Nanoparticles were optimized using an I-optimal experimental design evaluating PLGA concentration and surfactant type. The optimized SPION/OND-PLGA nanoparticles showed a small particle size (141.547 ± 1.31 nm), narrow size distribution (PDI = 0.235 ± 0.002), relatively high zeta potential (-34.307 ± 0.53 mV), and satisfactory encapsulation efficiency (42.09 ± 1.34%). The developed nanogel exhibited acceptable organoleptic properties, shear-thinning behavior, sustained drug release, and enhanced ex vivo nasal permeability, with OND permeation values of 996.96 ± 6.53 μg, 621.92 ± 7.54 μg, and 317.87 ± 2.88 μg per cm2 within 6 h for the nanogel,SPION/PLGA NPs and aqueous solution, respectively. In vivo behavioral studies (open field test and elevated plus maze) demonstrated significant anxiolytic activity in all OND-treated groups, with superior efficacy for the magnetically targeted nanogel. Neurochemical and biochemical analysis indicated a monoaminergic-dominant anxiolytic profile, increased BDNF expression, and improved oxidative stress status. Molecular docking revealed strong OND binding to 5-HT5A and 5-HT3A receptors. Overall, magnetic intranasal nanocarriers substantially enhanced the anxiolytic and neuroprotective efficacy of ondansetron.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OndansetronDrug CarriersAnxietyAnti-Anxiety AgentsMagnetic Iron Oxide NanoparticlesAnimalsRatsMaleParticle SizeAdministration, IntranasalPolylactic Acid-Polyglycolic Acid CopolymerDrug LiberationDrug Delivery SystemsAcrylic ResinsRats, Wistar

Stichwörter der Autor:innen

5-HT(3) receptorAnxietyMagnetic targetingOndansetronPLGA nanoparticlesRepurposingSPIONSuperparamagnetic iron oxide nanoparticles

Substanzen

OndansetronDrug CarriersAnti-Anxiety AgentsPolylactic Acid-Polyglycolic Acid Copolymercarbopol 940Acrylic Resins

Autor:innen und Institutionen

  • Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Capital University Previously Known as Helwan University, Cairo 11790, Egypt.
  • College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MUST), Giza, Egypt.
  • Department of Pharmaceutics, Faculty of Pharmacy, University of Sadat City, Sadat City 32897, Menoufia, Egypt. Electronic address: j_alsofany@hotmail.com.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El‑Aini Street, Cairo 11562, Egypt.
  • Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
  • Department of Clinical Laboratory Science, College of Applied Medical Sciences, King Saud University, Riyadh 11451, Saudi Arabia.

Zitieren

APA

Tantawy, N., Elsalhy, S., Alsofany, J. M., Saleh, A. M., Alshehri, S. M., Alqarni, S. S., El-Sayed, E. K., Ahmed, A. A., & El Naggar, E. E. (2026). Ondansetron-loaded magnetically targeted nanocarriers for anxiety: optimization, in vitro characterization, and in vivo evaluation in rats. European Journal of Pharmaceutics and Biopharmaceutics, 223, 115071. https://doi.org/10.1016/j.ejpb.2026.115071

Vancouver

Tantawy N, Elsalhy S, Alsofany JM, Saleh AM, Alshehri SM, Alqarni SS, et al. Ondansetron-loaded magnetically targeted nanocarriers for anxiety: optimization, in vitro characterization, and in vivo evaluation in rats. European Journal of Pharmaceutics and Biopharmaceutics. 2026;223:115071. doi:10.1016/j.ejpb.2026.115071

BibTeX
@article{Tantawy2026,
  author = {Tantawy, Norhan and Elsalhy, Soha and Alsofany, Jihad Mahmoud and Saleh, Abdulrahman M and Alshehri, Samiyah M and Alqarni, Sana Saeed and El-Sayed, Elsayed K and Ahmed, Asmaa A and El Naggar, Eman E},
  title = {Ondansetron-loaded magnetically targeted nanocarriers for anxiety: optimization, in vitro characterization, and in vivo evaluation in rats},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2026},
  volume = {223},
  pages = {115071},
  doi = {10.1016/j.ejpb.2026.115071}
}
Kostenlos starten →